Pharmacological disposition and metabolic fate of 2′-fluoro-5-iodo-1-β-D-arabinofuranosylcytosine in mice and rats was written by Chou, Ting-Chao; Feinberg, Aaron; Grant, Alan J.; Vidal, Pedro; Reichman, Uri; Watanabe, Kyoichi A.; Fox, Jack J.; Philips, Frederick S.. And the article was included in Cancer Research on September 30,1981.Quality Control of 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione The following contents are mentioned in the article:
2′-Fluoro-5-iodo-1-β-D-arabinofuranosylcytosine-HCl (FIAC)(I) [69123-90-6] was synthesized and labeled with 14C in the 2 position for the study of pharmacol. disposition and metabolic fate. FIAC is deaminated by cytosine nucleoside deaminase [9025-06-3] at a rate comparable to that of 1-β-D-arabinofuranosylcytosine. The deaminated product, 2′-fluoro-5-iodo-1-β-D-arabinofuranosyluracil (FIAU) [69123-98-4] is, like FIAC, an active antiviral agent. After i.v. injection of [2-14C]-FIAC in mice, most of the radioactivity in plasma appears as FIAU. In i.v.-injected rats which lack cytosine nucleoside deaminase, plasma radioactivity is largely present in unchanged FIAC. If mice are pretreated with tetrahydrouridine, an inhibitor of the nucleoside deaminase, plasma radioactivity is mostly FIAC. The radioactivity of [2-14C]-FIAC injected i.v. is excreted in urine, at 63 to 93% of the dose in mice and >90% of the dose in rats within 0 to 24 h. Most of the radioactivity in urine of rats and in mice pretreated with tetrahydrouidine is present as unchanged FIAC; in control mice, most of the radioactivity is found as FIAU. Chromatog. anal. of urine from control mice receiving labeled FIAC has revealed that radioactivity is present in the following nucleosides: FIAC (14.5); FIAU (73); 2′-fluoro-5-methyl-1-β-D-arabinofuranosyluracil (FMAU) [69256-17-3] (5.4); and 2′-fluoro-1-β-D-arabinofuranosyluracil [69123-94-0] (2.3%). These metabolites are also present in acid-soluble fractions of mouse blood, small intestine, and liver. Like FIAC and FIAU, FMAU is a potent antiherpetic agent. Only â?.3% of the radioactivity of injected [2-14C]-FIAC appears in mouse respiratory CO2; degradation to CO2 can be blocked by tetrahydrouridine. Less than 2% of the total radioactivity is excreted in bile in rats. Small amounts of radioactivity are also recovered in feces, mostly in deaminated products. FIAC and FIAU, with a 2′-F substituent in the arabino configuration, are less susceptible to metabolic glycosyl cleavage than is 5-iodo-2′-deoxyuridine. The radioactivity of [2-14C]-FIAC is incorporated into DNA fractions of highly proliferating organs such as intestine, spleen, and thymus, although preliminary results indicate that the substances incorporated are arabinofuranosyl nucleoside metabolites of FIAC. This study involved multiple reactions and reactants, such as 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3Quality Control of 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione).
1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3) belongs to pyrimidine derivatives. The pyrimidine ring system has wide occurrence in nature as substituted and ring fused compounds and derivatives. We all know its importance to life – pyrimidine and purine bases are included in the structure of DNA and RNA.Quality Control of 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione
69256-17-3;1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione;The future of 69256-17-3;New trend of C10H13FN2O5;function of 69256-17-3